Table 1.

Sensitivity of ependymoma cell models towards FGFR inhibitors given as IC₅₀ values

	Ponatinib (µM)	Nintedanib (µM)	AZD-4547 (µM)	Erdafitinib (µM)	Dovitinib (µM)
SP-EPN
VBT77	0.57	4.13	9.58
PF-A
VBT78	0.54	6.05	7.88
VBT131	3.48	4.76	> 10
VBT96	0.52 ± 0.02	2.95 ± 0.91	5.65 ± 0.02	0.52 ± 0.02	2.75 ± 0.61
VBT160	1.80	4.76	9.03
BT214	0.53 ± 0.1	2.61 ± 0.75	4.51 ± 2.93	5.44 ± 0.38	3.10 ± 0.90
ST-RELA
VBT73	0.95 ± 0.37	4.01 ± 1.95	4.27 ± 1.78
VBT145	0.80 ± 0.34	3.40 ± 0.48	5.16 ± 0.56
VBT211	0.73 ± 0.45	3.83 ± 1.19	4.50 ± 1.52	1.79 ± 0.21	2.31 ± 0.96
VBT242	2.23 ± 0.25	4.49 ± 1.74	5.67 ± 1.68	6.94 ± 0.74	7.35 ± 0.21
VBT371	0.50 ± 0.05	2.66 ± 0.58	2.11 ± 0.37	0.40 ± 0.07	2.03 ± 1.08
BT165	0.47 ± 0.21	4.23 ± 0.23	6.56 ± 0.83	2.25 ± 0.06	5.16 ± 0.86

Mean IC₅₀ values and standard deviations of repeated experiments (if available) for stable cell models are listed